Patent intelligence · US
US 12240816
Deuterated compounds and uses thereof
Deuterated compounds and uses thereof
Patent details — US 12240816
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 4, 2025
- Expiration
- Feb 27, 2045
- Applicant
- Aldeyra Therapeutics, Inc.
- Claims
- 20
- CPC classes
- A61K, A61K31/47, A61K45/06, A61P
Quick answer
US 12240816 (Deuterated compounds and uses thereof) is held by Aldeyra Therapeutics, Inc.. Status: granted. Granted Mar 4, 2025. Expires Feb 27, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Aldeyra Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K31/47, A61K45/06, A61P, A61P17/00, A61P27/02
More from Aldeyra Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12128013
Toxic aldehyde related diseases and treatment
granted -
US 12097188
Compositions and methods for the treatment of macular degeneration
granted -
US 12064516
Pharmaceutical formulations and uses thereof
granted -
US 12029735
Polymorphic compounds and uses thereof
granted -
US 12006298
Polymorphic compounds and uses thereof
granted -
US 12005060
Ophthalmic formulations of methotrexate
granted -
US 12005061
Ophthalmic formulations of methotrexate
granted
Frequently asked questions
What is US patent 12240816?
US 12240816 (Deuterated compounds and uses thereof) is held by Aldeyra Therapeutics, Inc.. Status: granted. Granted Mar 4, 2025. Expires Feb 27, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12240816?
Aldeyra Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 38 pharmaceutical patents for this assignee.
When does US 12240816 expire?
Our index shows an expiration date of Feb 27, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.